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Pervasive developmental disorders are now commonly referred to as autism spectrum disorders
(ASDs). ASDs present with a range of severity and impairments, and often are a cause of severe
disability, representing a major public health concern. The diagnostic criteria require delays or
abnormal functioning in social interaction, language, and/or imaginative play within the first 3 years of
life, resulting in a deviation from the developmental pattern expected for the age. Because
establishing a diagnosis of ASD is possible as early as 18-24 months of age, clinicians should strive to
identify and begin intervention in children with ASD as soon as signs are manifest. Increasing efforts
are underway to make ASD screening universal in pediatric healthcare. Given the crucial importance
of early identification and multiple modalities of treatment for ASD, this review will summarize the
diagnostic criteria, key areas for assessment by clinicians, specific scales and instruments for
assessment, and discussion of evidence-based treatment programs and the role of specific drug
therapies for symptom management.
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Introduction
According to the American Psychiatric Association’s
DSM-IV,1 the category of pervasive developmental
disorders (PDDs) includes autistic disorder, Asperger’s
disorder, pervasive developmental disorder not otherwise
specified (PDD-NOS), childhood disintegrative disorder
(CDD, Heller’s syndrome), and Rett’s disorder. This
group of disorders is characterized by a shared spectrum
of qualitative impairments in social interaction, associated
with varying degrees of deficits in communication and
marked repetitive behaviors and restricted interests.
PDDs are now commonly referred to as autism spectrum
disorders (ASDs). Diagnosing ASD requires a compre-
hensive, systematic, and structured approach. Besides
meeting the goal of identifying the disorder, the diagnostic
assessment provides important information on the child’s
relative strengths and weaknesses, identifies which
maladaptive behavior and comorbid difficulties are pre-
sent, clarifies the impact of the child’s condition on the
family, and benchmarks the developmental skills of the
patient. In this way, the assessment should establish a
roadmap for treatment by identifying the capabilities and
challenges for the child and providing useful information
on the needs and skills that must be addressed by
intervention. Because establishing a reliable diagnosis of
ASD is possible as early as 18-24 months of age,
clinicians should strive to identify and begin intervention
in children with ASD as soon as signs are manifest.2
Epidemiology
The pioneering epidemiologic study in autism was
conducted by Victor Lotter in the 1960s in England.3
Studies conducted after the 1990s detected estimates of
autistic disorder prevalence between 10 and 16 per
10,000 inhabitants, while the current estimated rates of
PDD are approximately 60/10,000,4,5 representing a
nearly 10-fold increase compared to earlier reports in
the literature. Epidemiologic surveys from around the
world have found individuals with ASD in all studied
regions, and with roughly similar prevalence rates.6 PDD-
NOS is routinely found to be the most frequent diagnosis
(3/1,000), followed by autistic disorder (2/1,000), while
Asperger’s disorder is significantly less common (6/
10,000). Rett’s disorder and CDD are very rare (2/
100,000).7 A recent study by the U.S. Centers for
Disease Control Prevention (CDC), using a surveillance
system, found an overall prevalence of approximately 1%
for ASD in several regions of the United States.8
Only four studies presenting epidemiological data from
Latin American countries have been published.6 In Brazil,
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a pilot study of the prevalence of ASD was conducted at a
local administrative area in the state of Sa˜o Paulo. The
study included 1,470 children aged 7 to 12 years old and
was based on a combination of standardized instruments
and clinical assessments using the DSM-IV criteria. The
survey estimated a prevalence of ASD of 0.3%, and some
hypotheses were raised to explain this low frequency, the
main one being the small sample size.9 Taken together,
the combined prevalence of ASDs makes them one of the
most frequent neurodevelopmental disorders, represent-
ing a major public health concern.
Diagnostic criteria
The current specific criteria for ASD diagnoses are drawn
from three domains:
i) Impaired social interaction, as shown by: a) marked
impairment in the use of non-verbal communicative
behaviors (such as eye-to-eye gaze, facial expression,
body postures); b) failure to develop age-appropriate
peer relationships; c) a lack of spontaneous sharing of
affect and interests with others; and d) lack of social or
emotional reciprocity (limited interest in or awareness of
others’ reactions, interests, or feelings).
ii) Qualitative impairments in communication skills, as
shown by: a) delays in, or lack of, language acquisition
(absence or reduced frequency of early language
development as babbling and playing with sounds,
and later, absence of phrase speech); b) inability to
initiate or maintain a conversation; c) stereotyped and
repetitive use of language or idiosyncratic language
(echolalia, oddly formal speech, neologisms); and d)
lack of development of age appropriate pretend play or
social imitative play.
iii) Presence of restricted and repetitive patterns of
behavior, interests and activities, as shown by: a)
pronounced preoccupation with one or more unusual
and restricted interests; b) inflexible adherence to
specific routines or rituals; c) motor stereotypies (hand
flapping, finger flicking, pacing, and jumping); and d)
preoccupations with parts of objects.
In order to meet full criteria for autistic disorder, the
individual must have evidence of a total of six or more
items from domains i), ii), and iii), with at least two items
from i), and one each from ii) and iii). Individuals with
Asperger’s disorder by definition are considered to have
no clinically significant language delays, and must
manifest two or more criteria from i) and at least one
criterion from repetitive, restricted interests (iii).The
diagnosis of PDD-NOS is considered a form of sub-
threshold autism or autism with atypical features in
individuals with severe and pervasive social commu-
nication impairments and/or impairing restricted inter-
ests and repetitive behaviors, but where the required
criteria for autistic disorder or Asperger’s disorder is not
met. Rett’s disorder and CDD have distinct develop-
mental and behavioral profiles (severe deceleration of
motor skills and head growth between 5 to 30 months for
Rett’s disorder and marked, pervasive developmental
and behavioral deterioration after apparently normal
development for at least 2 years in CDD).
The diagnostic criteria require the appreciation of
delays or abnormal functioning in social interaction,
language, and/or imaginative play within the first 3 years
of life, resulting in a deviation from the developmental
pattern expected for their age.10 Hence, a priority is to
identify early signs of ASD and initiate interventions as
soon as possible, as it is widely recognized that early
intervention results in a better prognosis.11 Longitudinal
studies of infants at high-risk for autism by virtue of
having an older affected sibling, and retrospective
examinations of first-birthday videos in children later
diagnosed with autism confirm that, in some children, the
delays and deviations of ASD are identifiable between 6
and 12 months of age,12 becoming more stable after 18
months of age.13 Autism diagnoses at 24 months of age
have been found to be stable over follow-up periods of
several years. Although the first symptoms described in
the literature are related to social communication, these
longitudinal studies have shown that infants with other
more non-specific signs not related to sociability can be
identified even earlier. These signs include irritability, lack
or excess of responsiveness, changes in activity level,
and deficits in gross motor development.14 Retrospective
reports from the CDC autism surveillance network noted
that more than 50% of parents of children with autism had
voiced concerns about their child’s development or
behavior in the first 12 months of life, and that 80% had
identified concerns about language development by 36
months.15 Clinicians are strongly encouraged to take note
of such early concerns and possible deviations and
consider intervention, rather than to suggest prolonged
monitoring.
The DSM-5 has just been officially released and in its
most recent text renames the category as ASD, with
significant changes in the diagnostic classification and
criteria for the PDDs as compared to the DSM-IV
according to a recent editorial on the subject.16 The
main changes in the diagnosis criteria are presented in
Table 1.
Screening evaluations
In the United States, pediatricians are recommended to
perform routine specific ASD screening at 18 and again at
24 months.17 The approach to screening assessments for
suspected ASD includes the following:
ASD specific symptom screening for DSM criteria in
primary care or general medical settings (Level 1).
These screening approaches can be performed using
completion of well validated checklists, such as the
Developmental Behavioral Checklist-Parent (DBC-
P),18 the Modified Children’s Autism Test (M-
CHAT),19 the Autism Behavior Checklist (ABC),20 or
the Autism Screening Questionnaire (ASQ).21 For
those children identified as high-risk for ASD by virtue
of positive initial screening, more in-depth assessments
should then be pursued (Level 2). These include:
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1) The Childhood Autism Rating Scale (CARS).22
2) Determination of social abilities and adaptive skills. The
Social Responsiveness Scale (SRS),23 completed by a
parent, can provide information relating to social
abilities. The Vineland Adaptive Behavior Scales
(Vineland-II, 2nd edition)24 can be administered by a
clinician or completed by parents to assess adaptive
skills.
3) Screening for maladaptive behaviors and comorbid
problems (e.g., hyperactivity, irritability, aggression,
temper outbursts, self-injury, mood, anxiety symptoms)
can be assessed by means of parent or caregiver
completion of the Aberrant Behavior Checklist-
Community Version (ABC-CV).25
4) Screening for medical comorbidities (history of elimina-
tion disorders, seizures, gastrointestinal problems,
growth abnormalities). The role of medical testing in
the assessment of ASD is increasing, although full
consensus is lacking as to what tests are considered
universally appropriate. Examples include possible
electroencephalogram testing, given that the rate of
comorbid epilepsy in ASD varies between 15-30%.
When epilepsy is present, a neurologist assessment
should be indicated.
5) Screening for indicators of genetic syndromes asso-
ciated with autism (family history, dysmorphic features,
head size, cafe´ au lait spots, inherited metabolic
disorders). Currently, it is recommended that if the
patient presents with mental retardation, minor physical
anomalies, syndromic features or family history,
genetic evaluation should be suggested. The indica-
tions for molecular genetic testing are rapidly expand-
ing, with many specialists now recommending
comparative genomic hybridization testing or whole-
exome sequencing for individuals with a confirmed
diagnosis of ASD.26
Diagnostic instruments
The accepted gold standard diagnostic assessments for
an ASD diagnosis are the Autism Diagnostic Observation
Schedule (ADOS)27 and the Autism Diagnostic Interview,
Revised (ADI-R)28 because of their extensive detail of
behavioral and developmental characterization, and their
reliability among raters trained in their administration. The
original ADI was established for research and was used
to evaluate the behavior of individuals older than 5 years,
whose chronological and mental age was at least 2 years,
based on diagnostic criteria proposed by the ICD-10 and
DSM-IV. Subsequently, the ADI-R was revised and
modified to be appropriate for children from mental ages
18 months through adulthood.
The ADOS is a semi-structured clinician-administered
interview that assesses a wide range of ASD-specific
characteristics including verbal and non-verbal commu-
nication, reciprocal interaction, and conversational ability.
It requires approximately 45 minutes for administration.
There are separate ADOS modules based on age,
language, and developmental level, such as the ADOS-
T for toddlers, and Modules 1-4 that are validated for
children, adolescents, and adults. It is important to note
that both ADI-R and ADOS need specialized training for
administration, but they can be administered by a wide
range of specialists. The ADI-R has already been
translated and validated in Brazil29 and there is a
Brazilian version of ADOS (personal communication by
Maria Clara Pacifico, Cristiane S de Paula, and Guiomar
Oliveira, 2012).
Complementary evaluations
Assessment of developmental level of intellectual abilities
Cognitive dysfunction is nearly ubiquitous in ASD and
important in determining overall functional capacity,
although the severity and breadth of cognitive deficits
vary widely in individuals on the spectrum.30 Additionally,
it is important for the differential diagnosis or co-occurring
diagnosis with mental retardation. In cases of patients
with autism, approximately 60-70% have some level of
intellectual disability (mental retardation), whereas most
individuals with Asperger’s disorder and PDD-NOS test in
the normal range of intelligence, albeit with frequent,
more compartmentalized areas of deficits.31 Conversely,
around 10% of individuals with ASD have remarkable
skills for their age (‘‘savants’’), often representing highly
specialized and restricted skills not in keeping with their
impaired global functioning.10 Even among those ASD
individuals deemed to be high-functioning, by virtue of
scoring within the normal range of full scale IQ measures,
neuropsychological testing routinely reveals cognitive
dysfunction, particularly on executive functions and social
Table 1 Changes in the diagnostic criteria for the PDDs in the DSM-5 (adapted from Ozonoff16)
1) The category of pervasive developmental disorders will be replaced with ASD.
2) Three symptom domains will be collapsed into two domains: social communication (comprising elements of impaired social interaction
and impaired communication), and restricted interests and repetitive behaviors.
3) Creation of a single diagnosis (ASD) with the elimination of Asperger’s disorder.
4) Rett’s disorder will be eliminated.
5) Number of symptoms condensed from 12 to seven merging criteria that were overlapping and eliminating symptoms that are not specific
to ASD (e.g., delayed development of language).
6) Inclusion of a new symptom of unusual sensory sensitivity within the restricted interests and repetitive behaviors domain.
7) Addition of a severity criterion that will clarify the nature of the spectrum, as well as its variability, such as intensity and duration of
symptoms, amount of impairment associated.
8) Establishment of a new social communication disorder category to provide diagnostic coverage to individuals who only have social
communication problems but do not display the repetitive and stereotyped behaviors of ASD.
ASD = autism spectrum disorder; PDD = pervasive developmental disorder.
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cognition, such as set-shifting, planning, inhibitory con-
trol, and theory of mind deficits.32
Assessment of developmental level of language
A speech therapist evaluation is important since approxi-
mately 20-30% of ASD individuals are nonverbal and
between 20 and 25% of them present a developmental
history of marked regression in terms of loss of previously
acquired language.33 Some pre-verbal skills, such as joint
attention, response to speech, gestures, imitation, and
symbolic play, are considered strong predictors for early
verbal communication.34,35 Identifying impairments of
these skills is important for intervention as these
represent foundational skills for language acquisition.
Delays are also seen in the transition from the use of
isolated to combined words. A study from Paul et al.36
showed that even children with ASD who have achieved
productive use of isolated words and have a repertoire in
their expressive vocabulary of 100 words at 28 months
are still at high risk to not progress to sentence production
with more than one word. In contrast, 28-month-old
children with typical development and who have the same
size of vocabulary repertoire are uniformly able to
combine words into phrases. Although many children
with ASD present significant progress in language in the
period from 24 to 48 months, with vocabulary expansion
and scores within the mental age showed by appropriate
tests of receptive and expressive abilities, their overall
communication ability remains impaired. While the lack of
acquisition of phrase speech by age 5 years has often
been cited as predicting severely limited lifetime language
development, recently descriptions of later emergence of
language have been described in a number of cases.37
When children with ASD begin to talk, some distinctive
features in the language form and content appear, such
as echolalia. Echolalia is the repetition of other’s speech
and it can be immediate or delayed, partial or total.
Echolalia was initially seen as an undesirable and
dysfunctional behavior, however, current studies38 suggest
children use it as a strategy to communicate. As language
skills improve, echolalia tends to disappear.38 The pronoun
inversion is another common behavior in the speech of
children with ASD and seems to be related to the nature of
deictic pronouns, which can be confusing for younger
children of the spectrum. In deictic pairs like I/you, the
reference changes depending on the viewpoint of the
speaker. Children with ASD have particular difficulty with
this concept due to the literalness of language and lack of
flexibility.39 Even when the subject produces words and
grammatically correct sentences, their speech reflects
fundamental flaws of understanding and expression of
attitudes and intentions. In general, children with ASD have
vocabulary with little information. Many start talking only
naming specific objects or figures.40
Several authors have attempted to define specific
profiles of the nature of language impairments in indivi-
duals with autism, Asperger’s disorder, semantic-prag-
matic syndrome, and specific language impairment.41-45
However, because many characteristics are found to be
overlapping and/or are interrelated, such differences are
often found to be subtle and highly individualized making a
speech evaluation necessary. In Table 2, characteristics of
each disorders are summarized. To sum up, it can be
concluded that children with ASD have more difficulties in
linguistic structure, interests, and social use of language.
Individuals with Asperger’s syndrome by definition display
fewer problems with linguistic structure, but do manifest
pragmatic difficulties, and deficits in the effective social use
of language. Children with semantic-pragmatic disorder, in
contrast, have difficulties in understanding linguistic
structures and social interest.46-48
Treatment
Over the past two decades, with the increased number of
infants and toddlers diagnosed with ASD, there is a need
for effective and appropriate interventions for the children
Table 2 Differential diagnosis of language disorders
Autism - Atypical verbal language, such as failures in the use of gestures, facial expressions, and gaze
exchange
- No verbalization or atypical forms, content and use of language (echolalia, pronoun reversal)
- Impairment in receptive language
- Commitment in symbolic play
- Restricted interests
Asperger’s syndrome - Absence of delayed speech
- Absence of cognitive impairment
- Ability to memorize large amounts of information
- Restricted interests
- Impairment in reciprocal social interaction
Specific language impairment - Delay in language development not overcome until 5 years old
- Difficulty with the structural aspects of language
- High occurrence of deviant phonological processes (not observed in the normal process of language
acquisition)
- Overuse of gestures and vocalizations
- Short speeches, often with inadequate cohesion and coherence
Pragmatic language impairment - Inability in understanding and maintaining conversation
- Failures of content and form in sentence construction
- Inappropriate social responses
- Tangential speech
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and their families that address core impairments and
co-occurring conditions.49 The National Research
Council (NRC)50 conducted a systematic review of
research on interventions for children with ASD from
birth through 8 years of age. Few well-controlled studies
were conducted to test the effectiveness of specific
modalities of intervention. Priority for instruction should
be in a) functional, spontaneous communication, b) social
instruction across settings, c) play skills, with a focus on
peer interaction, d) new skill maintenance and general-
ization in natural contexts, and e) functional assessment
and positive behavior support to address problem
behaviors. Intervention effects should be evaluated
regularly at 3-6 months intervals, focusing on: a) social
skills, b) communication skills, c) adaptive skills, d)
organizational skills. Table 3 shows the essential char-
acteristics of effective interventions for children with ASD
determined by the NRC. Lack of significant progress in
any domain over a 3-6 month period should prompt
modification of treatment approach or intensity.
Treatment approaches
Parent training
Parental and family involvement is considered an
essential element of intervention programs for children
with autism.50 The basic assumption of behavioral parent
training is that child behavior is learned and maintained
through contingencies within the family context and that
parents can be taught to change these contingencies in
order to promote and reinforce appropriate behavior.51
Evidence involving young children supports the recom-
mendation of parent training as an effective method for
increasing social skills. However, the manner in which
parents are incorporated into the intervention process is
important, as well as individualizing the parent education
program to consider different family needs and circum-
stances; not every parent benefits from traditional
behavioral parent education programs. Parent education
appears to work best with highly motivated and well-
functioning adults who are not coping with additional
psychological or life stressors, which interferes with their
acquisition and implementation of positive parenting
strategies.52 The literature documents the effectiveness
of parent education programs and the lack of main-
tenance of behavioral gains when parents do not
participate in their children’s interventions programs.53-55
Applied behavioral analysis
Applied behavior analysis (ABA) is the science of
behavior modification in which procedures derived from
the principles of operant learning are applied to improve
socially adaptive behavior and acquisition of new skills
through intensive practice and targeted reinforcement.56
ABA utilizes a process that begins with the development
of treatment plans outlining the purpose and function of
behavioral excesses or deficits, selection of appropriate
techniques, and continual evaluation and modification of
the treatment through systematic data collection.
Functional behavioral assessments are a related set of
assessment strategies that provide information on the
variables associated with a specific behavior.57 The
operant learning techniques used in ABA intervention
for ASDs children are:
- Positive reinforcement: use of praise, snack, food, toys to
increase desired behaviors;
- Shaping: rewarding approximations or components of a
desired behavior until target behavior is exhibited;
- Fading: reducing prompts to increase independence;
- Extinction: removal of reinforcement maintaining a pro-
blem behavior;
- Punishment: applying undesired stimulus to reduce
problem behaviors;
- Differential reinforcement: reinforcing a socially accepta-
ble alternate or absence of a behavior.
Intervention programs based on ABA are currently
viewed as the first-line treatment for ASD in early
childhood.58 Both the UCLA/Lovaas model and the
Early Start Denver Model (ESDM), which are compre-
hensive early intervention programs built on a framework
of ABA, have high quality research reports documenting
their efficacy,59 especially for improving cognitive perfor-
mance, language skills, and adaptive behavior. However,
in the seminal study evaluating the benefits of ESDM,
even after 2 years of intensive intervention (more than 20
hours/week), all children in the active treatment group still
met criteria for ASD, documenting the challenge of
ameliorating social deficits.60 The Early Intensive
Behavioral Intervention (EIBI) is a behavioral strategy
utilized in the Lovaas61 study and is the ABA model with
the strongest empirical support to date.57 EIBI utilizes
operant learning approaches to reduce problem beha-
viors and discrete trial training to develop new skills, such
as attention, imitation, receptive/expressive speech and
life skills. Core features of the EIBI are:
1) Focus on early development (children younger than 5
years);
2) Intensity (one-on-one and small group instruction, 20-
40 hours/week);
3) Adult-directed methods;
4) Systematic approach (breaking down skills into basic
components);
Table 3 Essential characteristics of effective interventions for children with autism spectrum disorder
1) Start intervention programs as earlier as possible.
2) Intensive treatment, 5 days a week for a minimum of 5 hours per day.
3) Use of repeated planned teaching opportunities that are structured over brief periods of time.
4) Sufficient individualized adult attention on a daily basis.
5) Inclusion of a family component, including parent training.
6) Mechanisms for ongoing assessment with corresponding adjustments in programming.
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5) Comprehensive nature (e.g., the targets include com-
munication, socialization, adaptive behaviors, problem
behaviors).
Treatment and Education of Autistic and Related
Communication-Handicapped Children (TEACCH)
TEACCH is a classroom based, clinical service and
professional training program, developed at the
University of North Carolina, at Chapel Hill, and started
in 1972 by Eric Schopler.62 This program has been
incorporated widely into North American educational
settings and has contributed significantly to the evidence
base of autism interventions. The TEACCH approach is
called structured teaching because it is based on
evidence and observation that individuals with autism
share a pattern of behaviors, such as the ways individuals
think, eat, dress, understand their world, and commu-
nicate. The essential mechanisms of structured teaching
consist of organizing the environment and activities in
ways that can be understood by the individuals; using
individuals’ relative strengths in visual skills and interest
in visual details to supplement relatively weaker skills;
using individuals’ special interests to engage them in
learning; and supporting self-initiated use of meaningful
communication.
Cognitive-behavioral therapy (CBT)
A growing number of reports have begun to provide
moderate evidence for the efficacy of CBT approaches
for school-age and young adolescents with ASD.55,63
Improvements in anxiety, self-help, and daily living skills
have been reported, with 78% of 7-11 year-olds in the
CBT-treated group rated as positive responders in one
trial.55 Such findings encourage the consideration of
modified CBT approaches to address anxiety in high-
functioning children with ASD, which is important given
that as many as 30-40% of children with ASD report high
levels of anxiety-related symptoms.
Pharmacological treatment for target symptoms
Pharmacological treatment in ASD is widely employed as
an adjunctive treatment approach in the majority of
individuals with ASD across the lifespan.64,65 The best-
established goals of pharmacotherapy are to control often
associated target symptoms, such as insomnia, hyper-
activity, impulsiveness, irritability, auto and hetero-
aggressiveness, inattention, anxiety, depression, obses-
sive symptoms, tantrums, anger attempts, repetitive
behaviors or rituals. Numerous studies have reported
an increased prevalence of psychiatric comorbidities in
this population.66,67 Simonoff et al. found that 70% of
subjects with ASD had at least one comorbid psychiatric
disorder and 41% had two or more diseases. Comorbid
symptoms often compound the functional impairments in
patients with ASD and may limit the effectiveness of non-
pharmacological interventions. At present, there are no
available drugs to treat the core social and communication
deficits of autism, although this is a subject of intensive
research efforts with agents such as arbaclofen, oxytocin,
and mGluR5 antagonists as examples of potentially
disorder-modifying treatments under study.
Despite varying levels of empirical support for some
targeted medication choices, drug treatment of children and
adults with ASD is common clinical practice. Around 45-
75% of children with ASD are medicated with psychotropic
drugs.64,65 Most commonly prescribed medicines, in order
of frequency, are antidepressants, antipsychotics, antic-
onvulsants, and stimulants, many of them without definitive
studies guiding their usage. It should be noted that most
psychotropic use in ASD is off-label, as there are currently
just two medications (risperidone and aripiprazole)
approved by the Food and Drug Administration (FDA),
and only for the treatment of associated behaviors.68
Based on parental reports, the most difficult behaviors
of children with ASD are low frustration threshold,
distractibility, irritability, inattention, hyperactivity, com-
pulsive repetition, isolation, mood instability, and stereo-
typed hand movements.69
Aggressive behavior and irritability
More than 50% of children with autism show self-
aggression, and as many as 14.6% practice severely
intense self-aggression that may lead to hospitalization,
institutionalization, removal from less restrictive school
settings, and a worse prognosis.70,71 The causes of
irritability and aggression are multifactorial: comprehen-
sion difficulties, decreased ability to communicate and
express their needs and desires, reduced confrontation
skills, conflict with colleagues and authority figures,
psychosocial dysfunction, undiagnosed pain, mood and
anxiety disorders.70 The first step to address the
aggressive behavior is to identify the cause and then
find the most appropriate therapeutic approach (beha-
vioral management and/or medication). First- and sec-
ond-generation antipsychotics have shown moderate to
large benefits in controlling aggressive symptoms in
autism.70 In 2002, the Research Units in Pediatric
Psychopharmacology (RUPP) Autism Network reported
on a multicenter clinical trial that evaluated the efficacy of
short- and long-term risperidone in children and adoles-
cents aged 5-17 years with autism accompanied by with
tantrums, aggression, self-injurious behavior.72 The results
showed that short-term risperidone treatment was mark-
edly superior to placebo in these cases (positive respon-
ders: 75 vs. 12%, respectively), reducing maladaptive
behaviors broadly, including decreased irritability (aggres-
sion, agitation, severe temper outbursts), decreased
hyperactivity, and reductions in stereotypies. Risperidone
treatment was well tolerated for up to 6 months; side effects
found to be common in earlier studies with haloperidol were
comparatively lower with risperidone. Drowsiness and
weight gain were the most commonly reported side effects.
Most of seven randomized clinical trials with risperidone,
two re-analyses and two association studies demonstrated
some efficacy regarding analyzed parameters (irritability,
aggressiveness, hyperactivity, general functioning)73-81
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with risperidone. Effective doses were low, averaging 2 mg
per day. There was no evidence of tolerance or need to
increase the dose in subjects followed for up to 6 months of
treatment. Recently, the FDA approved aripiprazole for
treatment of irritability in children with autism aged 6 to 17
years with severe irritability. Two double-blind, placebo-
controlled clinical trials showed that aripiprazole is effective
in treating irritability, hyperactivity, and stereotypies in
ASD.82-84 In addition, aripiprazole has been reported to be
well tolerated in dose ranges of 5-15 mg per day, and is
associated with lower mean weight gain compared to many
other atypical antipsychotics, as measured during the initial
8 weeks of exposure.
Two randomized clinical trials with few children with
ASD using haloperidol showed significant positive effects
on behavioral symptoms and global functioning.85,86
Using scales of autistic symptoms (ABC), Miral et al.87
compared the effects of haloperidol and risperidone
treatment with the latter being superior only for the total
score. These studies suggest a positive role of haloper-
idol for the treatment of children with severe or refractory
autism.73 However, extrapyramidal side effects are
common with haloperidol, increasing concern over
possible long-term effects of exposure in this population.
Other atypical antipsychotics need further clinical
evaluation. Olanzapine has not been studied in rando-
mized placebo-controlled trials in children or adults with
ASD. However, some case studies88,89 and an open
trial90 reported positive results. Additionally, a rando-
mized trial with a parallel control group treated with
haloperidol91 reported positive results, although patients
had significant weight gain. The prolonged use of
olanzapine may induce significant metabolic changes,
which hampers its use in children and adolescents with
ASD.92 Ziprasidone was studied in one open study (2007)
that included 12 adolescents with ASD treated with
ziprasidone, with doses ranging from 20 to 160 mg/day.
A 75% response rate to treatment was observed
according to the parameters of the Clinical Global
Impression (CGI). In addition, there was an improvement
in the ABC subscales of irritability and hyperactivity.
Ziprasidone did not cause weight gain, but a regular
increase in the QTc interval of 14.7 milliseconds in the
sample was described.93 Another open clinical study94
and a retrospective review of clinical records95 showed
promising results for ziprasidone in patients with ASD.
Double blind, placebo-controlled studies are needed to
validate the use of ziprasidone in this population. An open
trial with a small number of individuals concluded that
quetiapine was poorly tolerated and ineffective in ASD.96
There is no evidence to substantiate clozapine usage
taking into account the presence of potentially serious
side effects such as seizures and neutropenia, with only
case reports available.97
Repetitive behavior
Most studies of selective serotonin reuptake inhibitors
(SSRIs) have shown lack of clinically significant efficacy
in the treatment of repetitive behaviors and restricted
interests of autistic spectrum patients.98,99 Only one
methodologically relevant study showed some positive
results of a SSRI (fluoxetine) compared to placebo,100 but
improvements were small. In the largest study of the
treatment of repetitive behaviors in ASD comparing
citalopram to placebo, no benefits were found for
citalopram, and side effects, such as hyperactivity,
insomnia, and behavioral deterioration, were common.101
Interestingly, in contrast to studies in children, two,
rigorous, placebo-controlled studies showed benefits for
fluvoxamine and fluoxetine on measures of repetitive
behaviors for adults,102,103 however again the benefits in
the fluoxetine study were small relative to placebo. Taken
together, there is limited evidence to support the use of
SSRIs as treatment for repetitive behaviors in ASD. No
large-scale controlled trials have examined their effects
for the treatment of anxiety or depressive symptoms in
individuals with ASD.
Hyperactivity, impulsivity, and inattention
Symptoms of attention deficit hyperactivity disorder
(ADHD) are very common in individuals with ASD,
affecting between 28-74% of children.64,104 Short atten-
tion span is observed in 50% of children with autism,
hyperactivity in 49 and 21% according to parents and
teachers, respectively.105 Children with ASD and ADHD
have higher risk of suffering adverse effects from
stimulant treatment than typically developing children
with ADHD, showing lower rates of positive responders
and less symptomatic improvement.106 To date, only
clinical trials have been conducted with methylphenidate
and atomoxetine in ASD. Three randomized clinical trials
investigated the effects of methylphenidate in children
with ASD.107-109 Three doses of medication compared to
placebo were tested in a clinical trial with 66 participants
with ASD in a crossover design.109 This study was
classified as showing strong clinical evidence since 49%
of subjects were rated to be positive responders by virtue
of showing . 25% decrease in ADHD symptoms from
baseline and CGI-Improvement rating of much improved
or very much improved. However, 18% dropped out of the
trial due to inability to tolerate the medication.82 Two other
small studies with 10 and 13 children have been judged to
be solidly designed, leading to the determination of a
promising level of evidence for treatment with methyl-
phenidate for hyperactivity in children with ASD.82 Doses
examined were moderate in the RUPP study, based on
0.125, 0.25, and 0.5 mg/kg per dose, administered three
times daily, 0.125-0.5 mg/kg/day or, 0.3-0.6 mg/kg/day. A
small, randomized, controlled clinical trial was conducted
with atomoxetine, a selective inhibitor of the reuptake of
norepinephrine, in 16 children aged 5 to 15 years old with
autism and ADHD. The treatment resulted in a response
rate of 43% defined as a 25% improvement on the ABC-
Hyperactivity subscale and CGI. A significant improvement
over placebo in the hyperactivity/impulsivity subscale was
also observed.110 Adverse effects were relatively mild.73 A
recent European trial found evidence for superiority of
atomoxetine vs. placebo on ADHD symptom measures,
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but no difference in response rates, which were low
(21 vs. 9%, respectively).111
Sleep problems
Insomnia and sleep cycle disruptions are common in
ASD. Comparing the sleep patterns of 59 children with
ASD aged 4 to 10 years old with 40 controls, the authors
found a prevalence of 66% for moderate sleep disorders
in patients with ASD.112 The literature shows a preva-
lence rate of sleep disorders ranging from 40 to 86% in
ASD.113 These symptoms produce functional impairment
and increased irritability influencing patient outcome and
decreasing the family’s quality of life. Many medications
are used because of their sedative profile to treat sleep
disorders: second-generation antipsychotics, antihista-
mines, benzodiazepines, alpha-agonists; however, none
of them has been evaluated by a controlled clinical trial.
Supplemental melatonin has shown promise in treating
initial insomnia in children with autism, with several
studies replicating the improvement in sleep induction.114
In addition, this agent is well tolerated by patients. A
meta-analysis conducted in 2011 found 18 papers, of
which five were randomized placebo controlled clinical
trials that evaluated the use of 1 to 6 mg/day of melatonin
to treat sleep disorders in patients with ASD. All of them
reported significant improvement in total sleep duration,
number of awakenings, and reduced latency to sleep
onset.113
Seizures
Although most children with autism do not have seizures,
the risk of having seizures is still much higher than in
typical children. Among patients with autism, 20-25% will
have seizures. A recent study115 confirmed some
previous findings that 22% of participants developed
epilepsy. In the majority, seizures began after 10 years of
age. Generalized tonic-clonic seizures predominated
(88%). In over half (19/33), seizures occurred weekly or
less frequently and in the majority of individuals (28/31)
and were controlled with the use of one to two antic-
onvulsants. Epilepsy was associated with gender
(female), intellectual disability, and poorer verbal abilities.
Although the presence of epilepsy in the probands was
not associated with an increased risk of epilepsy in their
relatives, it was associated with the presence of a
broader autism phenotype in relatives. This indicates that
the familial liability to autism may be associated with the
risk for epilepsy in the proband. When seizures are
present, a neurological assessment is very important.
The effective and safe use of many anticonvulsants
requires regular needs blood drug level monitoring. It is
important to note that valproic acid, the most used
drug,116 can take several weeks to exert effects.
However, because it may have moderate benefits in
irritability and severe tantrum, valproic acid deserves
consideration in the context of both symptom targets.117
Topiramate can be used in a range of seizure types and
could be tried when either valproic acid or carbamazepine
has failed to stop seizures, or in situations where these
medications are contraindicated. Using topiramate could
be an important choice given the suggestion that
combined use with risperidone may increase benefits in
irritability in children with ASD. Topiramate may also have
beneficial effects in reducing antipsychotic-induced appe-
tite and weight increases.118,119
Conclusion
ASD represents a major public health concern as a
prevalent neurodevelopmental disorder with pronounced
risk for failure of adaptation across social, educational, and
psychological outcomes. Because the identification of
delays and deviations of ASD is possible as early as 18-
24 months of age, pediatricians should strive to identify
and begin intervention in children with ASD as soon as
signs are manifest. Specific scales and instruments should
be used to assess clinical manifestations and guide the
construction and monitoring of comprehensive treatment
programs. True recovery of autism is not reported in the
literature, but educational, psychosocial, and language
therapies, often combined with adjunctive treatments,
such as drug therapy for specific symptoms, are well
established for their benefits in ASD. The complex and
pervasive nature of ASD requires a team of multiple
professionals for accurate diagnosis and clinical care.
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